Walker R C, Zeuli J D, Temesgen Z
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
Drugs Today (Barc). 2016 Jan;52(1):7-16. doi: 10.1358/dot.2016.52.1.2404002.
Isavuconazole is a new azole antifungal drug with a broad antifungal spectrum that includes yeasts, molds and dimorphic fungi. Its prodrug, isavuconazonium sulfate, is currently approved in the United States and Europe for the treatment of the two of the most common and most challenging invasive fungal infections in clinical practice, invasive aspergillosis and invasive mucormycosis. It is available in both oral and intravenous formulations for once-a-day dosing and has favorable safety profile and drug interaction potential in comparison to voriconazole. Its role in the treatment of other fungal infections, besides aspergillosis and mucormycosis, remains to be determined. Similarly, its efficacy in prophylaxis against invasive fungal infections or its utility in patients with prior azole exposure is yet to be elucidated in clinical studies.
艾沙康唑是一种新型唑类抗真菌药物，具有广泛的抗真菌谱，包括酵母菌、霉菌和双相真菌。其前体药物硫酸艾沙康唑鎓目前在美国和欧洲被批准用于治疗临床实践中两种最常见且最具挑战性的侵袭性真菌感染，即侵袭性曲霉病和侵袭性毛霉病。它有口服和静脉注射两种剂型，每日给药一次，与伏立康唑相比，具有良好的安全性和药物相互作用潜力。除曲霉病和毛霉病外，其在治疗其他真菌感染中的作用仍有待确定。同样，其在预防侵袭性真菌感染方面的疗效或在先前接触过唑类药物的患者中的效用，在临床研究中仍有待阐明。
